Artivion Reports Strong Financial Growth and Innovations in Cardiac Surgery for 2024
- Artivion reported Q4 revenue of $97.3 million, a 4% increase, and full-year revenue of $388.5 million, up 10%.
- The company received FDA's Humanitarian Device Exemption for its AMDS Hybrid Prosthesis, marking a significant product milestone.
- Artivion's growth includes a 26% revenue surge in Latin America, showcasing successful market expansion and outreach efforts.
Artivion Advances in Cardiac and Vascular Surgery with Promising Financial Results and Innovations
Artivion, Inc., a leader in cardiac and vascular surgery, announces its financial results for the fourth quarter and full year of 2024, reflecting robust growth and significant advancements in its product offerings. The company reports a quarterly revenue of $97.3 million, marking a 4% increase from $93.7 million in the same period last year. For the full fiscal year, revenue reaches $388.5 million, an impressive 10% rise over the previous year’s $354.0 million. Despite a net loss of $(16.5) million in the fourth quarter, Artivion improves its overall financial position with a full-year loss of $(13.4) million, down from $(30.7) million in 2023.
The growth trajectory is complemented by a notable 15% increase in adjusted EBITDA to $17.6 million in Q4, while the annual adjusted EBITDA soars 32% to $71.3 million. Artivion's cash flow performance also stands out, with $22.2 million in operating cash flow and $11.0 million in non-GAAP free cash flow generated in 2024. This financial stability allows the company to invest further in its innovative product pipeline, which is critical in the fast-evolving cardiac and vascular markets.
A key highlight for Artivion is the receipt of a Humanitarian Device Exemption (HDE) from the FDA for its AMDS Hybrid Prosthesis, a significant milestone in its product development journey. The company also submits a second module of its pre-market approval application (PMA) to the FDA, signaling its commitment to regulatory compliance and market readiness. The revenue growth in Q4 is largely attributed to strong performances across its product lines, especially the On-X products and stent grafts, both of which saw a 10% increase. The most remarkable growth, however, comes from Latin America, where revenue surges by 26%. This expansion demonstrates Artivion's successful outreach and market penetration in emerging regions.
Beyond the financial metrics, Artivion's Chairman and CEO, Pat Mackin, underscores the significance of new clinical data from the AMDS PERSEVERE trial, which points to a 50% reduction in mortality at one year. This promising outcome not only emphasizes the life-saving potential of Artivion's technology but also reinforces the company’s mission to improve patient outcomes in cardiac care.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

